

cis-HALOVINYLTHTIOACETAMIDO SIDE CHAIN, A NEW EFFECTIVE
STRUCTURAL ELEMENT FOR 7 β -SUBSTITUTION IN
CEPHEM AND OXACEPHEM ANTIBIOTICS

II. 7 β -*cis*-FLUOROVINYLTHTIOACETAMINO-7 α -
METHOXY-1-OXACEPHEMS

YASUHIRO NISHITANI, TSUTOMU AOKI, TOSHIRO KONOIKE, HIROMU TAKAHASHI,
SADAO YAMAMOTO, YUTAKA NISHINO, MITSURU YOSHIOKA,
TERUJI TSUJI, YOSHIHIDE KOMATSU, SHINZO MATSUURA,
TADASHI YOSHIDA and WATARU NAGATA*

Shionogi Research Laboratories, Shionogi & Co., Ltd.,
Fukushima-ku, Osaka 553, Japan


(Received for publication August 19, 1987)

The synthesis and *in vitro* activity of 1-oxacephem derivatives having a substituted or a non-substituted *cis*-fluorovinylthioacetamido side chain at C-7 are described. Of these new 1-oxacephem antibiotics, 2355-S (42a) shows good antibacterial activity against Gram-positive and Gram-negative bacteria, and very favorable pharmacokinetic properties.

Latamoxef (moxalactam) (1), known as the first oxacephem antibiotic¹⁾, is currently used clinically as one of the representative so-called third-generation cephalosporins. The common feature of cephalosporins of this generation is their weakness against Gram-positive bacteria and their strength against Gram-negative bacteria. Latamoxef is not exceptional and is weak in its activity against Gram-positive bacteria.

This drawback was alleviated in flomoxef (2)²⁾, which is equally active against Gram-positive and Gram-negative bacteria. It is now under clinical study as a candidate for a new generation of β -lactams. In parallel with this work, we synthesized a large number of 1-oxacephem derivatives bearing variously substituted vinylthioacetamido C-7 side chains and examined their biological properties. Part of this study was reported in the preceding paper³⁾, in which we discussed mainly oxacephem derivatives bearing substituted or non-substituted *cis*-chlorovinylthioacetamido side chains. Among

Fig. 1.



them, oxacephem **3** was found to be the most attractive in both antibacterial activity and pharmacokinetics. However, we were disappointed to realize that its MICs were not reflected well in its protective effect on experimental infection in mice. A similar trend was also observed with oxacephems **4**, **5**, **6**, each of which has a chlorine atom in the vinylthioacetamido C-7 side chain, as shown in Table 2. We thought that replacement of chlorine by fluorine would improve such unfavorable properties and investigation along this line confirmed our strategy. We finally found a new oxacephem 2355-S (**42a**), which exhibited more favorable pharmacokinetic properties than flomoxef (**2**). The present paper describes the synthesis and the biological properties of 2355-S and the related oxacephem derivatives.

Chemistry

After several unsuccessful trials, we eventually could prepare *cis*-fluorovinylthioacetic acid (**14**) starting from fluoroethyl *p*-toluenesulfonate (**7**)⁴⁾ (Fig. 2). The tosylate **7** was treated with thioglycolate and triethylamine in *N,N*-dimethylformamide to give **8**. Chlorination of **8** with excess chlorine at 0°C in methylene chloride afforded the dichloride **9**, which was oxidized with *m*-chloroperbenzoic acid (MCPBA) into the sulfoxide **10**. The sulfoxide **10** was less reactive and could be reduced to the sulfide **9** when subjected to Pummerer reaction using SOCl₂, Ac₂O or (CF₃CO)₂O with or without base. This reaction could also be done using a combination of trifluoromethanesulfonic anhydride and 2,6-di-*tert*-butyl-4-methylpyridine even at a low temperature, providing **12** directly in *ca.* 90% yield as a single product. It is noteworthy that no *trans* isomer was detected on the NMR spectrum. This high stereo-selectivity suggests that a conformer with fluorine and sulfonium cation oriented in the *Gauche* situation may be most stable in the transition state **11**. Studies on this problem will be published elsewhere. Reduction of **12** with zinc in CH₂Cl₂ containing acetic acid, followed by saponification, gave **14** in a good yield.

Carbamoyl- and *N*-methylcarbamoyl-fluorovinylthioacetic acids (**18** and **19**) were conveniently synthesized by two methods, A and B. In method A (Fig. 3), Claisen condensation of ethyl monofluoroacetate with ethyl formate was effected in ether by the procedure of ELKIK *et al.*⁵⁾ to give a rather unstable sodium enolate **15**, which was mesylated with mesyl chloride to afford **16** as a single geometrical isomer. The *cis* assignment of the fluorine atom to the mesyl in **16** was based on the observed large coupling constant ($J_{HF}=16$ Hz) in the NMR spectrum. The mesylate **16** was reacted with thio-

Fig. 2.




Fig. 3.






Fig. 4.



glycolic acid in the presence of two equivalents of triethylamine in *N,N*-dimethylformamide at room temperature affording **17** with complete retention of the stereochemistry. From a practical point of view, it is worthy to note that these three steps could be conveniently carried out in one pot with 50% overall yield from ethyl fluoroacetate. Aminolysis of **17** with ammonium hydroxide or aqueous methylamine in ethanol followed by acidification gave **18** and **19**, respectively.

To avoid the use of toxic ethyl monofluoroacetate, we searched for other useful methods and were able to establish method B (Fig. 4) which involves carbene insertion to vinyl acetal **20** or **21** and subsequent pyrolysis of the resultant cyclopropanes **22** or **23** as key reactions^{6,7}. Thus, chlorofluorocarbene, generated *in situ* from Freon **21** (dichlorofluoromethane) with potassium *tert*-butoxide in hexane at $-20^\circ\text{C} \sim -10^\circ\text{C}$ was captured with ketene diethylacetal (**20**) giving 1,1-diethoxy-2-chloro-2-fluorocyclopropane (**22**) in 60% yield. To avoid possible polymerization of the expected pyrolysis product **24**, the pyrolysis of **22** was carried out by heating it at 140°C in 1,2,4-trichlorobenzene in the presence of trace amounts of hydroquinone and the resulting α -fluoroacrylate was removed from the

Fig. 5.



reaction mixture by concomitant distillation to give **24**[†] in 76% yield. Bromination of **24** with bromine in CCl₄ under reflux and subsequent base treatment provided α -fluoro- β -bromoacrylate **26a** in a completely stereo-selective manner. Although we thus obtained **26a** in an acceptable yield, we still found that it was not suitable for large-scale preparation of **26a** because the operation was complicated by the instability of the key intermediate **24**. On the other hand, pyrolysis of the cyclopropane **22** could be more conveniently carried out by heating it with a slight excess of ethanol and pyridine in refluxing benzene. Unlike the former case, the product obtained in 70% yield was **27** in this case, providing us with an excellent practical method. Bromination of **27** in carbon tetrachloride at 5°C followed by hydrolysis with 2 N HCl in ethanol gave **25**[†] in good yield.

In an alternative procedure, chlorofluorobutoxycyclopropane (**23**), prepared in good yield by addition of chlorofluorocarbene to butyl vinyl ether (**21**), was converted to **31** via the ring-opened acetal **28** and the brominated product **30**. The acetal **31** was then subjected to oxidative cleavage of the acetal moiety with persulfate to give **26b** in 60% yield. After our study was completed, NGUYEN *et al.*⁹⁾ reported an analogous method for preparation of phenyl ester **26**. Compounds **26a** and **26b** were finally transformed into **18** or **19** by the same procedure as applied to the mesylate **16**.

The carboxylic acids **14**, **18** and **19** were coupled with the methoxyamine **33** using a combination of phosphorous oxychloride and pyridine to afford the corresponding acylamino derivatives **34**, **35** and **36**. These 3-chloromethyl-1-oxacephems reacted with various *N*-substituted mercaptotetrazoles **37a**~**37d** in *N,N*-dimethylformamide or in a two-phase system with a catalytic amount of Bu₄N⁺Br⁻ to give **38a**~**38d**, **39a**~**39d** and **40a**~**40d**, respectively, in quantitative yields. Removal of the benzhydryl group was performed by a well-established procedure using AlCl₃ and anisole to give the

[†] An alternative synthetic method of **24** and **25** has been previously reported by M. HUDLICKY. Literature bp **24**, 110°C (728 mm); **25**, 67~67.5°C (3.2 mm), see ref 8.

free oxacephems¹⁰), which were neutralized with sodium bicarbonate and purified by chromatography (Diaion HP-20) to give the corresponding sodium salts **41a**~**41d**, **42a**~**42d** and **43a**~**43d** in a pure state.

Biology

The MICs of those oxacephem antibiotics bearing *cis*-fluorovinylthioacetamido C-7 side chains are shown in Table 1. All of these compounds show excellent antibacterial activity against both Gram-positive and Gram-negative bacteria, and a good parallelism between their *in vitro* and *in vivo* activity in marked contrast with the corresponding chloro analogues (Table 2). C-7 non-substituted fluorovinylthioacetamido analogues **41a**~**41d** proved to be the most active and showed antibacterial activity comparable to those of the chloro congeners. Compounds **42** and **43** having additional groups (CONH₂, CONHCH₃) show slightly decreased activity but more favorable pharmacokinetic properties compared with **41** (Table 3). In every series, modification of the C-3' position with variously substituted tetra-

Table 1. MIC ($\mu\text{g/ml}$) of 1-oxacephem antibiotics **41**, **42** and **43**.

Compound	S.a. JC-1	S.a. C-14	E.c. NIHJC-2	E.c. 73	K. sp. 363	P.m. PR-4	P.v. CN-329
41a	0.2	0.2	0.05	0.1	0.05	0.1	0.2
41b	0.1	0.2	0.05	0.1	0.05	0.1	0.2
41c	0.2	0.4	0.1	0.2	0.05	0.1	0.2
41d	0.1	0.2	0.2	0.8	0.1	0.2	0.4
42a	0.4	0.4	0.05	0.1	0.05	0.2	0.4
42b	0.4	0.4	0.05	0.1	0.05	0.1	0.4
42c	0.4	0.8	0.05	0.1	0.05	0.2	0.4
42d	0.2	0.4	0.2	0.4	0.05	0.2	0.2
43a	0.4	0.8	0.05	0.2	0.1	0.2	0.4
43b	0.4	0.4	0.05	0.2	0.05	0.1	0.2
43c	0.8	0.8	0.2	0.4	0.1	0.2	0.4
43d	0.2	0.4	0.4	1.6	0.2	0.4	0.8

Abbreviations: S.a.; *Staphylococcus aureus*, E.c.; *Escherichia coli*, K.; *Klebsiella*, P.m.; *Proteus mirabilis*, P.v.; *Proteus vulgaris*.

Table 2. Activity of 1-oxacephem antibiotics in mouse protection tests^a.

Compound	<i>Streptococcus pyogenes</i> C-203			<i>Escherichia coli</i> EC-14		
	MIC ($\mu\text{g/ml}$)	ED ₅₀ (mg/kg)	(ED ₅₀ /MIC)	MIC ($\mu\text{g/ml}$)	ED ₅₀ (mg/kg)	(ED ₅₀ /MIC)
3	0.05	2.11	(42)	0.2	0.33	(1.7)
4	0.8	19.3	(24)	0.01	0.042	(4.2)
5	0.05	3.35	(67)	0.05	0.054	(1.1)
6	0.05	2.69	(54)	0.05	0.18	(3.6)
41a	0.2	3.27	(16)	0.05	0.12	(2.4)
42a	0.1	1.92	(19)	0.05	0.087	(1.7)
42b	0.1	1.43	(14)	0.05	0.12	(2.4)

^a Mice dosed 1 and 5 hours post infection.

Table 3. Plasma levels of 1-oxacephem antibiotics **41**, **42** and **43** in monkeys.

Compound	41a	41b	42a	42b	43a	43b
AUC ($\mu\text{g}\cdot\text{hours/ml}$)	20	30	42	52	51	50
Half life (minutes)	27	35	39	50	53	61

Dose: 20 mg/kg, iv.

zolythio groups had only little influence on the activity. Taking the overall biological properties into account, **42a**, designated as 2355-S, was selected for further biological evaluation¹¹⁾.

Experimental

MP and BP were uncorrected. ¹H NMR spectra were recorded at 60 MHz on a Varian T-60 NMR Spectrometer and at 90 MHz on a Varian EM-390 NMR Spectrometer using TMS as an internal (in organic solvent) or external (in D₂O) standard. ¹⁹F NMR spectra were determined on a Varian EM-360 with C₆F₆ as the internal reference. IR spectra were recorded on Hitachi 260-10 and 215 Spectrometers. Anhydrous solvents dried over Molecular Sieves type 4A were used for reactions under anhydrous conditions.

Methyl (2-Fluoroethylthio)acetate (8)

Methyl thioglycolate (2.2 ml, 24.6 mmol) was dissolved in DMF (20 ml), and 5.2 N NaOCH₃ - MeOH (4 ml, 20.8 mmol) and the tosylate **7** (4.36 g, 20 mmol) were added. After being stirred for 1.5 hours at room temp, the reaction mixture was partitioned between ether and water, and the organic layer was dried and evaporated. The residue was distilled to give 2.85 g of **8** (93.8%): BP 100~102°C/17 mmHg; IR (CHCl₃) 1730 cm⁻¹; ¹H NMR (CDCl₃) δ 2.95 (2H, dt, *J*=21 and 6 Hz), 3.30 (3H, s), 3.75 (3H, s), 4.60 (2H, dt, *J*=47 and 6 Hz).

Sulfoxide 10

A solution of chlorine (1 M solution in CCl₄, 10 ml, 10 mmol) was added to the sulfide **8** (0.75 g, 4.93 mmol) in CH₂Cl₂ (10 ml) under ice cooling. After 5 minutes the reaction mixture was evaporated *in vacuo* to give the crude dichloride **9** (0.91 g): ¹H NMR (CDCl₃) δ 3.33 (2H, dt, *J*=22 and 7 Hz), 3.90 (3H, s), 4.67 (2H, dt, *J*=46 and 7 Hz). The dichloride **9** was dissolved in CH₂Cl₂ (15 ml) and 80% MCPBA (1.1 g, 5.10 mmol) in CH₂Cl₂ (20 ml) was added (the reaction was monitored by TLC). The reaction mixture was washed with aq Na₂SO₃ solution, aq NaHCO₃ solution and brine, dried and evaporated to dryness. Chromatography on silica gel gave 0.83 g of the sulfoxide **10** (70.4%); IR (CHCl₃) cm⁻¹ 1760, 1750; ¹H NMR (CDCl₃) δ 2.57~3.67 (2H, m), 3.97 (3H, s), 4.43~5.47 (2H, m).

Methyl (cis-Fluorovinylthio)dichloroacetate (12)

Trifluoromethanesulfonic anhydride (7.5 ml, 44.6 mmol) was slowly added to a mixture of the sulfoxide **10** (9.7 g, 40.6 mmol) and 2,6-di-*tert*-butyl-4-methylpyridine (23.5 g, 114.4 mmol) in anhydrous CH₂Cl₂ (80 ml) at -30°C. After being stirred for 30 minutes at the same temp, the resulting white precipitates were filtered off and the filtrate was washed with water, dried and evaporated *in vacuo*. The residue was chromatographed on silica gel to afford **12** (8.0 g, 89.2%) as an oil: IR (CHCl₃) 1750 cm⁻¹; ¹H NMR (CDCl₃) δ 3.93 (3H, s), 5.87 (1H, dd, *J*=4 and 36 Hz), 6.93 (1H, dd, *J*=4 and 80 Hz).

Methyl (cis-Fluorovinylthio)acetate (13)

To a solution of the dichloride **12** (8 g, 36.5 mmol) in CH₂Cl₂ (80 ml) containing MeOH (5 ml) and AcOH (5 ml), zinc (8.0 g) was portion wise added over 10 minutes under ice-cooling. After stirring for another 10 minutes at the same temp, the reaction mixture was filtered. The filtrate was washed with dilute HCl (2 times) and brine, dried and evaporated to yield **13** (5.8 g, 106%) as an oil: IR (CHCl₃) 1730 cm⁻¹; ¹H NMR (CDCl₃) δ 3.38 (2H, s), 3.75 (3H, s), 5.53 (1H, dd, *J*=4 and 38 Hz), 6.68 (1H, dd, *J*=4 and 82 Hz).

(cis-Fluorovinylthio)acetic Acid (14)

To the ester **13** (5.8 g, 38.7 mmol) in MeOH (20 ml) at 0°C, 2 N NaOH (19.5 ml, 39 mmol) was added. After 20 minutes at 0°C, the reaction mixture was partitioned between water and ether, and the aqueous layer was acidified with 2 N HCl and extracted twice with EtOAc. The combined extract was washed with brine, dried and evaporated to dryness to give the acid **14** (5.4 g, 103%): IR (CHCl₃) cm⁻¹ 3100, 1710; ¹H NMR (CDCl₃) δ 3.42 (2H, s), 5.50 (1H, dd, *J*=38 and 4 Hz), 6.72 (1H, dd, *J*=81 and 4 Hz).

Mesylate 16

To a suspension of NaH (60% in mineral oil, 8.65 g, 216.3 mmol) in anhydrous butyl ether (200 ml), anhydrous ethanol (12.7 ml, 216.4 mmol) was added dropwise. After being stirred for 1 hour at room temp, a mixture of ethyl fluoroacetate (20 g, 118.5 mmol) and ethyl formate (23 ml, 270 mmol) was slowly added over 10 minutes, and the mixture was stirred for 3 hours. Anhydrous DMF (100 ml) was added to dissolve the gummy precipitate and the resultant clear solution was cooled to -5°C and mesyl chloride (14.6 ml, 188.6 mmol) was added. After stirring for 30 minutes at 0°C and 30 minutes at room temp, the reaction mixture was poured into water and extracted with EtOAc. The extract was washed with brine, dried and evaporated to give the crude mesylate **16** in ca. 60% yield: IR (CHCl_3) cm^{-1} 1730, 1680; ^1H NMR (CDCl_3) δ 1.33 (3H, t, $J=7$ Hz), 3.23 (3H, s), 4.32 (2H, q, $J=7$ Hz), 7.40 (1H, d, $J=16$ Hz).

((Z)-2-Fluoro-2-ethoxycarbonylvinylthio)acetic Acid (17)

A mixture of thioglycolic acid (3.28 ml, 47.2 mmol) and triethylamine (14.5 ml, 104 mmol) in DMF (5 ml) was added to the mesylate **16** (10 g, 47.2 mmol) in DMF (30 ml) at $10\sim 20^{\circ}\text{C}$. After 1.5 hours at room temp the reaction mixture was partitioned between ether and water. The aqueous layer was acidified with 3% HCl and extracted with EtOAc (2 to 3 times). The combined extract was washed with water, dried and evaporated to afford the acid **17** (8.07 g, 90.5%) as an oil: IR (CHCl_3) cm^{-1} 1715, 1615; ^1H NMR (CDCl_3) δ 1.33 (3H, t, $J=7$ Hz), 3.62 (2H, s), 4.30 (2H, q, $J=7$ Hz), 6.98 (1H, d, $J=32$ Hz), 10.45 (1H, br s).

(2-Fluoro-2-carbamoylvinylthio)acetic Acid (18)

The half ester **17** (0.54 g, 2.6 mmol) was dissolved in 28% ammonium hydroxide (2 ml) and the resulting solution was allowed to stand overnight at room temp. After condensation *in vacuo* to ca. 10 ml followed by acidification with conc HCl, the resulting crystals were filtered and washed with ice water to afford 0.43 g of **18** (92.4%): MP $204\sim 206^{\circ}\text{C}$; IR (Nujol) cm^{-1} 3430, 3210, 1710, 1660, 1640, 1610, 1580; ^1H NMR ($\text{DMSO}-d_6$) δ 3.72 (2H, s), 6.90 (1H, d, $J=36$ Hz), 7.40~8.10 (2H, m).

(2-Fluoro-2-methylcarbamoylvinylthio)acetic Acid (19)

A mixture of the half-ester **17** (6.0 g, 28.9 mmol) and 40% methylamine solution in water (0.97 ml) was stirred for 2 hours at room temp. After removal of the excess methylamine *in vacuo*, the reaction mixture was diluted with water (10 ml) and then acidified with conc HCl. The resulting crystals were filtered and washed with a minimum amount of ice water to afford **19** (2.73 g). IR (Nujol) cm^{-1} 3280, 3090, 1720, 1660, 1615, 1600, 1550; ^1H NMR ($\text{DMSO}-d_6$) δ 2.67 (3H, d, $J=5$ Hz), 3.72 (2H, s), 6.83 (1H, d, $J=35$ Hz).

1,1-Diethoxy-2-chloro-2-fluorocyclopropane (22)

To a suspension of potassium *tert*-butoxide (14.5 g, 129.2 mmol) in anhydrous hexane (95 ml) containing ketene diethylacetal (10 g, 86.2 mmol), dichlorofluoromethane (25 g, 242.7 mmol) in anhydrous hexane (50 ml) was added at $-20\sim -10^{\circ}\text{C}$ over 35 minutes. After stirring at the same temp for 1 hour, the reaction mixture was poured into water and extracted with hexane. The extract was washed with aq NaHCO_3 solution and water, dried and distilled to give **22** (9.31 g, 59.2%): BP $54\sim 57^{\circ}\text{C}/20$ mmHg; ^1H NMR (CDCl_3) δ 1.24 (6H, t, $J=7.5$ Hz), 1.17~1.88 (2H, m), 3.78 (4H, q, $J=7.5$ Hz); ^{19}F NMR (CDCl_3) δ +15.92 (dd, $J=9.4$ and 18.8 Hz).

Ethyl α -Fluoroacrylate (24)

The cyclopropane **22** (6.1 g, 33.4 mmol) in 1,2,4-trichlorobenzene (TCB) (6.1 g) was added dropwise to TCB (6.1 g) containing a trace amount of *p*-hydroquinone at 145°C under reduced (360 mmHg) nitrogen atmosphere. The distillate collected bp $40\sim 45^{\circ}\text{C}$ (360 mm), was **24** (3.0 g, 76%): IR (CHCl_3) cm^{-1} 1730, 1660, 1325, 1175, 1100; ^1H NMR (CDCl_3) δ 1.32 (3H, t, $J=7.5$ Hz), 4.29 (2H, q, $J=7.5$ Hz), 5.29 (1H, dd, $J=3$ and 13.5 Hz), 5.65 (1H, dd, $J=3$ and 44 Hz); ^{19}F NMR (CDCl_3) δ 44.1 (1H, dd, $J=13.16$ and 43.24 Hz).

Ethyl α -Fluoro- β -bromoacrylate (26a)

Bromine (2.7 g, 16.9 mmol) was added to a solution of **24** (2.0 g, 16.9 mmol) in CCl_4 (50 ml).

After heating under reflux, the reaction mixture was washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ solution and water, dried and evaporated *in vacuo*. The residue was dissolved in benzene (47 ml) and heated under reflux with DBU (2.35 ml, 15.7 mmol). After cooling and filtration of the resultant precipitate, the filtrate was washed with water and evaporated to give an oily residue (2.69 g), which when purified by distillation gave **26a** (2.15 g, 64.6%): BP 80°C/40 mmHg; ^1H NMR (CDCl_3) δ 1.33 (3H, t, $J=7.5$ Hz), 4.31 (2H, q, $J=7.5$ Hz), 6.93 (1H, d, $J=24$ Hz).

Triethyl Orthofluoroacrolate (27)

The cyclopropane **22** (5 g, 27.4 mmol) was heated under reflux in anhydrous benzene (25 ml) with anhydrous ethanol (2.38 ml, 40.6 mmol) and pyridine (2.65 ml, 33.1 mmol) for 1 hour. The reaction mixture was washed with water, dried and distilled under reduced pressure to yield 3.7 g of **27** (91.2%): BP 73~77°C/40 mmHg; IR (CHCl_3) cm^{-1} 1678, 1097; ^1H NMR (CDCl_3) δ 1.20 (9H, t, $J=7.5$ Hz), 3.54 (6H, q, $J=7.5$ Hz), 4.94 (1H, dd, $J=16.5$ and 2.3 Hz), 4.99 (1H, dd, $J=48$ and 2.3 Hz); ^{19}F NMR (CDCl_3) δ +45.5 (dd, $J=16.9$ and 48.9 Hz).

Ethyl α,β -Dibromo- α -fluoropropionate (25) from 27

To a solution of the orthoacrylate **27** (4.58 g, 30.95 mmol) in anhydrous CCl_4 (46 ml), bromine (1.22 ml, 24 mmol) in CCl_4 (10 ml) was added dropwise at 5°C over 20 minutes. After 5 minutes, the reaction mixture was washed with aq 5% $\text{Na}_2\text{S}_2\text{O}_3$ solution and water, dried and evaporated to give an oily residue (7.4 g). It was stirred in EtOH (130 ml) containing 2 N HCl (41 ml) at room temp. After 1 hour, the mixture was poured into water and extracted with hexane (3 times). The combined extract was washed, dried and distilled to yield **25** (5.18 g, 60.2%): BP 79~85°C/15 mmHg; IR (CHCl_3) cm^{-1} 1765, 1310, 1043; ^1H NMR (CDCl_3) δ 1.37 (3H, t, $J=7.5$ Hz), 3.90~4.52 (2H, m), 4.40 (2H, q, $J=7.5$ Hz).

1-Chloro-1-fluoro-2-butoxycyclopropane (23)

To an ice-cooled mixture of *n*-butyl vinyl ether (60 g, 0.6 mol), Adogen 464 (10 g) and dichlorofluoromethane (120 g, 1.165 mol) in a three-necked flask equipped with a dry-ice condenser, KOH (66 g, 1.176 mol) in H_2O (45 ml) was slowly added over 30 minutes under vigorous stirring. After being stirred at room temp for 4 hours, additional dichlorofluoromethane (120 g, 1.165 mol) and KOH (66 g, 1.176 mol) in H_2O (45 ml) were added, and the mixture was stirred for 2 hours. The reaction mixture was partitioned between ether and water. Distillation of the organic layer *in vacuo* gave **23** (65.05 g, 65.1%): BP 43~45°C/7 mmHg; IR (film) cm^{-1} 1170, 1125, 1080; ^1H NMR (CDCl_3) δ 0.91 (3H, t, $J=7$ Hz), 1.15~1.85 (6H, m), 3.3~3.8 (3H, m).

α -Fluoroacrolein Dibutylacetal (28)

A mixture of **23** (42 g, 252.3 mmol), butanol (150 ml) and pyridine (24 ml, 300 mmol) was heated under reflux for 17 hours. The reaction mixture was partitioned between ether and aq K_2CO_3 solution. The organic layer was separated and its distillation gave **28** (36.9 g, 76.6%): BP 83~85°C/10~12 mmHg; IR (film) cm^{-1} 1680, 1115, 1070; ^1H NMR (CDCl_3) δ 0.93 (6H, t, $J=7$ Hz), 1.2~1.8 (8H, m), 3.35~3.75 (4H, m), 4.80 (1H, dd, $J=50$ and 3 Hz), 4.80 (1H, dd, $J=17$ and 3 Hz), 4.92 (1H, d, $J=3$ Hz).

α -Fluoro- β -bromoacrolein Dibutylacetal (31)

Bromine (14.4 g, 90.1 mmol) was added to a solution of **28** (18.1 g, 94.8 mmol) in CCl_4 (150 ml), under ice cooling. After stirring for 1.5 hours at room temp, the reaction mixture was condensed *in vacuo* to give the dibromide **30**. It was dissolved in CH_2Cl_2 (150 ml) and heated under reflux with DBU (16.2 g, 106.2 mmol) for 4 hours. The reaction mixture was diluted with CH_2Cl_2 , washed successively with dilute HCl, aq K_2CO_3 solution and water, dried and evaporated. Purification of the residue by distillation gave 17.85 g of **31** (69.7%): BP 96~98°C/4 mmHg; IR (film) cm^{-1} 1670, 1100, 1070; ^1H NMR (CDCl_3) δ 0.91 (6H, t, $J=7$ Hz), 1.15~1.75 (8H, m), 3.35~3.75 (4H, m), 4.97 (1H, s), 5.94 (1H, d, $J=28$ Hz).

Butyl α -Fluoro- β -bromoacrylate (26b)

Caro's acid (7.8 g) was added to a solution of the acetal **31** (4.29 g, 15.9 mmol) in butanol (15 ml),

and the mixture was stirred for 2 hours at room temp. Additional Caro's acid (3.91 g) was added and stirring was continued for 1 hour at room temp and 1 hour at 50~60°C. The reaction mixture was partitioned between CH₂Cl₂ and water. The organic layer was distilled to give 2.98 g of **26b** (61%): BP 73~75°C/5 mmHg; IR (film) cm⁻¹ 1735, 1643; ¹H NMR (CDCl₃) δ 0.8~2.0 (7H, m), 4.23 (2H, t, *J*=6 Hz), 6.87 (1H, d, *J*=24 Hz).

7α-Methoxy-7β-(*cis*-fluorovinylthio)acetamido-3-chloromethyl-1-oxacephem (**34**)

To a solution of the methoxy-amine **33** prepared from **32** (19.14 g, 36.77 mmol) in CH₂Cl₂ (200 ml), pyridine (12.1 ml), the carboxylic acid **14** (5.4 g, 39.7 mmol) and phosphorous oxychloride (3.53 ml, 37.9 mmol) were successively added at -30°C. After being warmed to 0°C over 20 minutes, the reaction mixture was washed with dilute HCl and water, dried and evaporated to dryness. Recrystallization of the solid residue from CH₂Cl₂ - ether afforded **34** (11.0 g, 56% from **32**): MP 197~199°C; IR (Nujol) cm⁻¹ 3250, 1776, 1720, 1680, 1654; ¹H NMR (DMSO-*d*₆) δ 3.42 (2H, s), 3.47 (3H, s), 4.53 (4H, br s), 5.20 (2H, s), 5.75 (1H, dd, *J*=42 and 4 Hz), 6.88 (1H, s), 6.2~7.66 (12H, m).

7α-Methoxy-7β-(2-fluoro-2-carbamoylvinythio)acetamido-3-chloromethyl-1-oxacephem (**35**)

To a solution of the methoxy-amine **33** prepared from **32** (4.1 g, 7.88 mmol) in CH₂Cl₂ (30 ml) were added pyridine (1.6 ml) and a mixture of the carboxylic acid **18** (1.32 g, 7.37 mmol) and pyridine (0.5 ml, 6.25 mmol) in anhydrous DMF (4 ml). After being cooled to -30°C, phosphorous oxychloride (0.56 ml, 6 mmol) was added dropwise and the mixture was stirred for 30 minutes at the same temp. Usual work-up gave a solid residue which was purified by chromatography and recrystallized from CH₂Cl₂ - ether to afford **35** (2.37 g, 52.1% from **32**): MP 160°C; IR (CHCl₃) cm⁻¹ 3390, 1780, 1715, 1690, 1630; ¹H NMR (DMSO-*d*₆) δ 3.45 (3H, s), 3.63 (2H, s), 4.55 (4H, br s), 5.23 (1H, s), 6.93 (1H, s), 6.97 (1H, d, *J*=32 Hz), 7.20~7.77 (13H, m).

7α-Methoxy-7β-(2-fluoro-2-*N*-methylcarbamoylvinythio)acetamido-3-chloromethyl-1-oxacephem (**36**)

From the carboxylic acid **19** (17.9 g, 92.7 mmol) and **32** (59.6 g, 114.5 mmol) the same procedure as **35** afforded **36** (49.5 g, 73.1% from **25**): MP 178~180°C; IR (CHCl₃) cm⁻¹ 3440, 3360, 1785, 1720, 1690, 1635; ¹H NMR (DMSO-*d*₆) δ 2.68 (3H, d, *J*=5 Hz), 3.47 (3H, s), 3.65 (2H, s), 4.55 (4H, br s), 5.23 (1H, s), 6.93 (1H, s), 6.67~8.50 (12H, m), 9.30 (1H, br s).

General Procedure of **38**~**40**

Sodium heterocyclic thiolate **37** (2.2 mmol) in DMF (2 ml) was added to a solution of the 3-chloromethyl-1-oxacephem **34**~**36** (2 mmol) in DMF (5 ml) under ice cooling. After 30 minutes, the reaction mixture was partitioned between water and EtOAc, and the organic layer was washed twice with water, dried and evaporated *in vacuo*. The residue was chromatographed to give the product **38**~**40** in more than 90% yield.

38a: IR (CHCl₃) cm⁻¹ 3350, 1782, 1700, 1623; ¹H NMR (CDCl₃) δ 3.38 (2H, br s), 3.55 (3H, s), 3.77~4.10 (2H, m), 4.10~4.40 (4H, m), 4.57 (2H, br s), 5.03 (1H, s), 5.43 (1H, dd, *J*=40 and 4 Hz), 6.87 (1H, s), 6.23~7.73 (12H, m).

38b: IR (CHCl₃) cm⁻¹ 3330, 1780, 1708, 1623; ¹H NMR (CDCl₃) δ 3.35 (2H, br s), 3.50 (3H, s), 3.92~5.13 (7H, m), 5.43 (1H, dd, *J*=40 and 4 Hz), 6.83 (1H, s), 5.92~7.77 (14H, m).

38c: IR (CHCl₃) cm⁻¹ 3340, 1785, 1672, 1630; ¹H NMR (CDCl₃) δ 2.70 (3H, d, *J*=5 Hz), 3.40 (2H, s), 3.56 (3H, s), 4.17 (2H, br s), 4.57 (2H, br s), 4.81 (2H, br s), 5.03 (1H, s), 5.47 (1H, dd, *J*=38 and 4 Hz), 6.72 (1H, s), 5.97~7.67 (13H, m).

38d: IR (Nujol) cm⁻¹ 3200, 3160, 1780, 1726, 1650; ¹H NMR (CDCl₃) δ 3.38 (2H, s), 3.55 (3H, s), 4.60~6.10 (8H, m), 6.66 (1H, dd, *J*=81 and 4 Hz), 6.90 (1H, s), 7.20~7.60 (11H, m).

39a: IR (CHCl₃) cm⁻¹ 3500, 3380, 1783, 1700, 1630; ¹H NMR (CDCl₃) δ 3.50 (2H, br s), 3.57 (3H, s), 3.70~4.80 (8H, m), 5.03 (1H, s), 5.90~6.47 (2H, m), 6.78 (1H, d, *J*=34 Hz), 6.90 (1H, s), 7.2~7.8 (12H, m).

39b: IR (KBr) cm⁻¹ 3375, 1785, 1680, 1660; ¹H NMR (Me₂CO-*d*₆) δ 3.52 (3H, s), 3.70 (2H, s), 4.2~4.4 (2H, m), 4.63 (2H, br s), 5.12 (3H, s), 6.70~7.77 (16H, m).

39c: IR (KBr) cm⁻¹ 3380, 1786, 1720, 1680, 1630; ¹H NMR (Me₂CO-*d*₆) δ 2.77 (3H, d, *J*=9 Hz),

3.55 (3H, s), 3.72 (2H, s), 4.22 (2H, br s), 4.63 (2H, br s), 5.07 (2H, s), 5.13 (1H, s), 6.90 (1H, s), 6.77~7.77 (15H, m).

39d: IR (CHCl₃) cm⁻¹ 3500, 3400, 1785, 1700, 1630; ¹H NMR (CDCl₃) δ 3.53 (5H, s), 4.26 (2H, s), 4.5~6.2 (9H, m), 6.70 (1H, s), 6.89 (1H, d, *J*=36 Hz), 7.2~7.9 (1H, m).

40a: IR (CHCl₃) cm⁻¹ 3450, 3360, 1783, 1700, 1672, 1640; ¹H NMR (CDCl₃) δ 2.73 (3H, d, *J*=5 Hz), 3.52 (5H, s), 3.73~4.80 (8H, m), 5.02 (1H, s), 6.25~6.70 (1H, m), 6.75 (1H, d, *J*=34 Hz), 6.87 (1H, s), 7.1~7.77 (11H, m).

40b: IR (KBr) cm⁻¹ 3430, 3340, 1780, 1715, 1685, 1620; ¹H NMR (DMSO-*d*₆) δ 2.67 (3H, d, *J*=5 Hz), 3.42 (3H, s), 3.65 (2H, s), 4.10~4.43 (2H, m), 4.47~4.78 (2H, m), 5.03 (2H, br s), 5.17 (1H, s), 6.88 (1H, s), 6.68~8.33 (14H, m).

40c: IR (CHCl₃) cm⁻¹ 3430, 3320, 1780, 1710, 1680, 1630; ¹H NMR (CDCl₃) δ 2.7~2.9 (6H, m), 3.57 (5H, s), 4.20 (2H, br s), 4.57 (2H, br s), 4.90 (2H, s), 5.07 (1H, s), 6.82 (1H, d, *J*=34 Hz), 6.88 (1H, s), 7.30~7.77 (13H, m).

40d: IR (CHCl₃) cm⁻¹ 3450, 3360, 1785, 1700, 1675; ¹H NMR (CDCl₃) δ 2.90 (3H, d, *J*=4 Hz), 3.58 (5H, s), 3.70 (2H, s), 4.70 (2H, s), 4.83 (1H, s), 5.0~6.2 (5H, m), 6.95 (1H, s), 6.5~7.8 (13H, m).

General Procedure for Removal of the Protecting Group of **41**~**43**

A solution of aluminum chloride (5~10 mmol) in anisole (5~10 ml)/nitromethane (5~10 ml) was added to the ester **38**~**40** (1 mmol) in anhydrous CH₂Cl₂ (5~10 ml) at -10°C. After 30 minutes at the same temp, the reaction mixture was poured into ice water and extracted with 2-butanone (3 times). The combined extract was washed with brine and re-extracted with aq NaHCO₃ solution. After being washed with EtOAc, the aqueous extract was brought to pH 2 with 1 N HCl and extracted several times with a mixture of 2-butanone - ethyl acetate (1:1). The combined extract was washed with brine, dried and evaporated *in vacuo*. The residue was dissolved in Me₂CO (10 ml) and water (5 ml), and the pH of the solution was brought to 6 by adding aq NaHCO₃ solution. The solution was condensed to 5 ml, re-adjusted at pH 6 and freeze-dried to obtain the sodium salt **41**~**43**.

41a: IR (KBr) cm⁻¹ 3420, 1770, 1685, 1630, 1610; ¹H NMR (D₂O) δ 3.95 (5H, s), 4.22~5.07 (8H, m), 5.60 (1H, s), 6.08 (1H, dd, *J*=40 and 4 Hz), 7.28 (1H, dd, *J*=82 and 4 Hz).

41b: IR (KBr) cm⁻¹ 3400, 1766, 1688, 1630, 1606; ¹H NMR (D₂O) δ 3.63 (5H, s), 4.57~4.70 (2H, m), 4.95 (2H, br s), 5.25 (1H, s), 5.38 (2H, s), 6.03 (1H, dd, *J*=40 and 4 Hz), 7.28 (1H, dd, *J*=81 and 4 Hz).

41c: IR (KBr) cm⁻¹ 3340, 1767, 1678, 1610; ¹H NMR (D₂O) δ 3.28 (3H, s), 4.00 (5H, s), 4.68 (2H, s), 5.00 (2H, br s), 5.65 (1H, s), 5.70 (2H, s), 6.08 (1H, dd, *J*=40 and 4 Hz), 7.36 (1H, dd, *J*=82 and 4 Hz).

41d: IR (KBr) cm⁻¹ 3330, 1760, 1680, 1610; ¹H NMR (D₂O) δ 3.98 (3H, s), 4.65 (2H, s), 4.98 (2H, s), 5.4~6.7 (7H, m), 7.39 (1H, dd, *J*=83 and 5 Hz).

42a: IR (KBr) cm⁻¹ 3400, 1770, 1680, 1605; ¹H NMR (D₂O) δ 3.97 (3H, s), 4.17 (2H, s), 4.33~5.10 (8H, m), 5.58 (1H, s), 7.30 (1H, d, *J*=34 Hz).

42b: IR (KBr) cm⁻¹ 3375, 1765, 1685, 1607; ¹H NMR (D₂O) δ 3.97 (3H, s), 4.15 (2H, s), 4.50, 4.77 (2H, ABq, *J*=13 Hz), 4.92 (2H, br s), 5.57 (1H, s), 5.70 (2H, s), 7.27 (1H, d, *J*=34 Hz).

42c: IR (KBr) cm⁻¹ 3400, 1770, 1680, 1610; ¹H NMR (D₂O) δ 3.25 (3H, s), 3.97 (3H, s), 4.15 (2H, s), 4.57~4.73 (2H, m), 4.75 (2H, br s), 5.60 (1H, s), 5.67 (2H, s), 7.37 (1H, d, *J*=34 Hz).

42d: IR (KBr) cm⁻¹ 3380, 1760, 1678, 1600; ¹H NMR (D₂O) δ 4.00 (3H, s), 4.17 (2H, s), 4.55, 4.74 (2H, ABq, *J*=12 Hz), 4.88, 5.02 (2H, ABq, *J*=10 Hz), 5.4~6.8 (6H, m), 7.37 (1H, d, *J*=33 Hz).

43a: IR (KBr) cm⁻¹ 3400, 1768, 1665, 1610; ¹H NMR (D₂O) δ 3.25 (3H, s), 3.97 (3H, s), 4.13 (2H, s), 4.33~4.73 (4H, m), 4.87~5.03 (4H, m), 5.58 (1H, s), 7.25 (1H, d, *J*=34 Hz).

43b: IR (Nujol) cm⁻¹ 3300, 1760, 1675, 1605; ¹H NMR (D₂O) δ 3.27 (3H, s), 3.95 (3H, s), 4.12 (2H, s), 4.5~4.7 (2H, m), 4.90 (2H, br s), 5.57 (1H, s), 5.70 (2H, s), 7.21 (1H, d, *J*=34 Hz).

43c: IR (Nujol) cm⁻¹ 3250, 1765, 1670, 1610; ¹H NMR (CDCl₃) δ 3.23 (6H, s), 3.95 (3H, s), 4.13 (2H, s), 4.53~4.72 (2H, m), 4.90 (2H, br s), 5.55 (1H, s), 5.62 (2H, s), 7.20 (1H, d, *J*=35 Hz).

43d: IR (KBr) cm⁻¹ 3400, 1782, 1668, 1608; ¹H NMR (D₂O) δ 3.26 (3H, s), 4.00 (3H, s), 4.54, 4.73 (2H, ABq, *J*=12 Hz), 4.8~6.8 (8H, m), 7.28 (1H, d, *J*=34 Hz).

Acknowledgments

We thank Dr. T. TSUSHIMA for his helpful discussions.

References

- 1) OKUDA, H.; W. NAGATA, M. YOSHIOKA, M. NARISADA, T. YOSHIDA, Y. HARADA & H. YAMADA: Discovery and development of moxalactam (6059-S): The chemistry and biology of 1-oxacephems. *Med. Res. Rev.* 1: 217~248, 1981
- 2) TSUJI, T.; H. SATOH, M. NARISADA, Y. HAMASHIMA & T. YOSHIDA: Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotics. *J. Antibiotics* 38: 466~476, 1985
- 3) NISHITANI, Y.; T. AOKI, T. YOSHIDA & W. NAGATA: *cis*-Halovinylthioacetamido side chain, a new effective structural element for 7 β -substitution in cephem and oxacephem antibiotics. I. 7 β -*cis*-Chlorovinylthioacetamino-7 α -methoxy-1-oxacephems. *J. Antibiotics* 41: 316~331, 1988
- 4) HOWELL, W. C.; J. E. MILLINGTON & F. L. M. PATTISON: Toxic fluorine compounds. VII. *o*-Fluoroalkyl thiocyanates and *o*-fluoroalkyl mercaptans. *J. Am. Chem. Soc.* 78: 3843~3846, 1958
- 5) ELKIK, E.; M. QUDOTTE & H. NORMANT: α -Fluoro- α -formyl ketones and esters. Preparation and study of some derivatives. *C.R. Acad. Sci. Ser. C* 274: 1579~1582, 1972
- 6) NERDEL, F.; J. BUDDRUS, W. BRODOWSKI, P. HENTSCHEL, D. KLAMANN & P. WEYERSTAHL: Reaction of dihalocarbens with enolethers. *Liebigs Ann. Chem.* 710: 36~58, 1967
- 7) SCHLOSSER, M.; Y. BESSIERE & D. N. SAVARY: Solvolytic ring-opening of alkoxychlorofluorocyclopropanes: A ready access to fluorinated α,β -unsaturated aldehydes and ketones. *Helv. Chim. Acta* 60: 1739~1746, 1977
- 8) HUDLICKY, M.: Synthesis of 7-fluoroglutaric acid. *Tetrahedron Lett.* 1960: 21~22, 1960
- 9) NGUYEN, T.; H. MOLINES & C. WAKSELMAN: Thermolysis of the chlorofluorocarbene 1-ethoxy-1-phenoxyethylene adduct to phenyl 2-fluoroarylate. *Synth. Commun.* 15: 925~930, 1985
- 10) TSUJI, T.; T. KATAOKA, M. YOSHIOKA, Y. SENDO, Y. NISHITANI, S. HIRAI, T. MAEDA & W. NAGATA: Synthetic studies on β -lactam antibiotics. VII. Mild removal of the benzyl ester protecting group with aluminum trichloride. *Tetrahedron Lett.* 1979: 2793~2796, 1979
- 11) KOMATSU, Y.; W. NAGATA, S. MATSUURA, Y. HARADA, T. YOSHIDA & S. KUWAHARA: 2355-S, a new broad-spectrum oxacephem for parenteral use: Laboratory evaluation. Program and Abstracts of the 24th Intersci. Conf. on Antimicrob. Agents Chemother. No. 645, p. 201, Washington, D.C., Oct. 8~10, 1984